Cancer often develops from precursor lesions, known as precancerous lesions. In the case of cervical or vulvar cancer, these are cervical intraepithelial neoplasia (CIN) and vulvar intraepithelial neoplasia (VIN), which are usually caused by infection with the human papillomavirus (HPV). A recent study by the University of Graz has now compared two different treatment options for these precancerous lesions. The conventional treatment involves surgically removing the lesions. However, the procedure is associated with side effects such as impaired wound healing, scarring or sexual discomfort. In addition, the condition may recur. Alternatively, the immune system can be stimulated by certain medicines to attack and destroy the diseased cells. The substance (imiquimod) can be applied by the patients themselves in cream form and causes local inflammation at the site of application, enabling the immune system to specifically destroy precancerous lesions. In a direct comparison of the two methods involving 110 women with VIN, the results were comparable between the two approaches, reports study leader Gerda Trutnovsky. It is important, however, that the well-tolerated ointment is used regularly, two to three times a week, and that follow-up examinations are carried out. Provided these conditions are met, the treatment represents a new therapeutic approach for women who wish to avoid the disadvantages of surgery whilst still opting for a safe and promising treatment to prevent cancer at an early stage. Reference: MedUni Graz Topical imiquimod as first-line treatment for vulvar intraepithelial neoplasia, Lancet 2022; https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)00624-9/fulltext
Cervical and vulvar cancer: smear tests rather than surgery